NCT05768932 2025-10-15
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
Phase 1 Recruiting
Clinical Trials
4 trialsNCT06586099 2024-09-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT06536959 2024-08-05
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
Phase 2 Recruiting
NCT04541277 2020-09-09
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
Phase 2 Unknown